Takeaway: Live biotherapeutic matches donor FMT in treating recurrent C. diff infection

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Medical illustration comparing manufactured biotherapeutic capsules to traditional fecal microbiota transplant procedure
Phase 1b trial shows manufactured 15-strain biotherapeutic achieves similar efficacy to traditional fecal transplant in treating recurrent C. difficile infection. Both treatments demonstrated 85-90% success rates. — Photo: National Institute of Allergy and Infectious Diseases / Pexels
1 min read|33 words

Key findings from C. diff biotherapeutic trial: 1) Manufactured 15-strain product matched FMT efficacy (85-90% success) 2) Both treatments showed comparable bacterial engraftment 3) Single-donor approach enables standardized microbiome therapy

Read the full article on GMJ Newsroom →

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Ethiopia Study Reveals Stakeholder Concerns Over Novel Malaria Treatments

A qualitative study in Ethiopia reveals that health workers and patients view…

Sitafloxacin monotherapy matches doxycycline-rifampicin for brucellosis treatment in landmark trial

A multicenter randomized trial in The Lancet Regional Health – Western Pacific…

Ultra-processed foods linked to higher kidney cancer risk in large US study

A prospective analysis of over 300,000 US adults found that higher consumption…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like